Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade

References

• World Health Organization (WHO). Global tuberculosis report 2013 [Online]. Geneva: WHO; 2013. Available at: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1
   Google Scholar
• Velasquez GE, Becerra MC, Gelmanova IY, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis 2014;59:9–15
   PubMed Web of Science ®Google Scholar
• Gandi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575–80
   PubMed Web of Science ®Google Scholar
• Rawat R, Whitty A, Tonge PJ. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc Natl Acad Sci USA 2003;100:13881–6
   PubMed Web of Science ®Google Scholar
• Vale N, Gomes P, Santos HA. Metabolism of the antituberculosis drug ethionamide. Curr Drug Metabol 2013;14:151–8
   PubMed Web of Science ®Google Scholar
• Barry CE 3rd, Lee RE, Mdluli K, et al. Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res 1998;37:143–79
   PubMed Web of Science ®Google Scholar
• Vilcheze C, Baughn AD, Tufariello J, et al. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother 2011;55:3889–98
   PubMed Web of Science ®Google Scholar
• Massengo-Tiassé RP, Cronan JE. Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci 2009;66:1507–17
   PubMed Web of Science ®Google Scholar
• Rozwarski DA, Vilcheze C, Sugantino M, et al. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J Biol Chem 1999;274:15582–9
   PubMed Web of Science ®Google Scholar
• Parikh S, Moynihan DP, Xiao G, Tonge PJ. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochem 1999;38:13623–34
   PubMed Web of Science ®Google Scholar
• Lu XY, Huang K, You QD. Enoyl acyl carrier protein reductase inhibitors: a patent review (2006–2010). Expert Opin Ther Patents 2011;21:1007–22
   PubMed Web of Science ®Google Scholar
• Tonge PJ, Kisker C, Slayden RA. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. Curr Top Med Chem 2007;7:489–98
   PubMed Web of Science ®Google Scholar
• Maresca A, Vullo D, Scozzafava A, et al. Inhibition of the β-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids. J Enzyme Inhib Med Chem 2013;28:392–6
   PubMed Web of Science ®Google Scholar
• Maresca A, Scozzafava A, Vullo D, Supuran CT. Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three β-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013;28:384–7
   PubMed Web of Science ®Google Scholar
• Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013;28:407–11
   PubMed Web of Science ®Google Scholar
• Pan P, Tonge PJ. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr Top Med Chem 2012;12:672–93
   PubMed Web of Science ®Google Scholar
• McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998;394:531–2
   PubMed Web of Science ®Google Scholar
• Ward WH, Holdgate GA, Rowsell S, et al. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochem 1999;38:12514–25
   PubMed Web of Science ®Google Scholar
• Pidugu LS, Kapoor M, Surolia N, et al. Structural basis for the variation in triclosan affinity to enoyl reductases. J Mol Biol. 2004;343:147–55
   PubMed Web of Science ®Google Scholar
• Jones RD, Jampani HB, Newman JL, Lee AS. Triclosan: a review of effectiveness and safety in health care settings. Am J Infect Control 2000;28:184–96
   PubMed Web of Science ®Google Scholar
• Freundlich JS, Wang F, Vilcheze C, et al. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. Chem Med Chem 2009;4:241–8
   Web of Science ®Google Scholar
• Sullivan TJ, Truglio JJ, Boyne ME, et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 2006;1:43–53
   PubMed Web of Science ®Google Scholar
• Betts JC, McLaren A, Lennon MG, et al. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:2903–13
   PubMed Web of Science ®Google Scholar
• Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Dis 2006;5:730–9
   PubMed Web of Science ®Google Scholar
• Boshoff HI, Myers TG, Copp BR, et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 2004;279:40174–84
   PubMed Web of Science ®Google Scholar
• Boyne ME, Sullivan TJ, am Ende CW, et al. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrob Agents Chemother 2007;51:3562–7
   PubMed Web of Science ®Google Scholar
• am Ende CW, Knudson SE, Liu N, et al. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett 2008;18:3029–33
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev 2001;46:3–26
   PubMed Web of Science ®Google Scholar
• Freundlich JS, Anderson JW, Sarantakis D, et al. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4′-substituted triclosan derivatives. Bioorg Med Chem Lett 2005;15:5247–52
   PubMed Web of Science ®Google Scholar
• Lu H, England K, am Ende C, et al. Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. ACS Chem Biol 2009;4:221–31
   PubMed Web of Science ®Google Scholar
• Luckner SR, Liu N, am Ende CW, et al. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J Biol Chem 2010;285:14330–7
   PubMed Web of Science ®Google Scholar
• Lu H, Tonge PJ. Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol 2010;14:467–74
   PubMed Web of Science ®Google Scholar
• Pan P, Knudson SE, Bommineni GR, et al. Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy. Chem Med Chem 2014;9:776–91
   Google Scholar
• Kuo MR, Morbidoni HR, Alland D, et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase. J Biol Chem 2003;278:20851–9
   PubMed Web of Science ®Google Scholar
• Menendez C, Gau S, Lherbet C, et al. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents. Eur J Med Chem 2011;46:5524–31
   PubMed Web of Science ®Google Scholar
• Menendez C, Chollet A, Rodriguez F, et al. Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents. Eur J Med Chem 2012;52:275–83
   PubMed Web of Science ®Google Scholar
• He X, Alian A, Stroud R, Ortiz de Montellano PR. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J Med Chem 2006;49:6308–23
   PubMed Web of Science ®Google Scholar
• Matviiuk T, Rodriguez F, Saffon N, et al. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis. Eur J Med Chem 2013;70:37–48
   PubMed Web of Science ®Google Scholar
• Matviiuk T, Mori G, Lherbet C, et al. Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis. Eur J Med Chem 2014;71:46–52
   PubMed Web of Science ®Google Scholar
• He X, Alian A, Ortiz de Montellano PR. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem 2007;15:6649–58
   PubMed Web of Science ®Google Scholar
• Pauli I, dos Santos RN, Rostirolla DC, et al. Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach. J Chem Inf Model 2013;53:2390–401
   PubMed Web of Science ®Google Scholar
• Castro PJ, Fernandez MR, Fernandez VEP, et al. 3-Amino-pyrazole derivatives useful against tuberculosis. Patent no.: WO2012049161 A1. Google Patents; 2012. Available from: http://www.google.com/patents/WO2012049161A1?cl=fr
   Google Scholar
• Shirude PS, Madhavapeddi P, Naik M, et al. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. J Med Chem 2013;56:8533–42
   PubMed Web of Science ®Google Scholar